



## A novel, microwave-assisted method for the synthesis of alicyclic-condensed 5H-1,4,6,7-tetrahydro-1,4-diazepin-5-ones

Árpád Balázs<sup>a</sup>, Erik Van der Eycken<sup>c</sup>, Ferenc Fülöp<sup>a,b,\*</sup>

<sup>a</sup>Institute of Pharmaceutical Chemistry, University of Szeged, H-6720 Szeged, Eötvös u. 6, Hungary

<sup>b</sup>Stereochemistry Research Group of the Hungarian Academy of Sciences, University of Szeged, H-6720 Szeged, Eötvös u. 6, Hungary

<sup>c</sup>Laboratory for Organic and Microwave-Assisted Chemistry (LOMAC), K.U. Leuven, Celestijnenlaan 200F, B-3000 Leuven, Belgium

### ARTICLE INFO

#### Article history:

Received 15 April 2008

Revised 30 April 2008

Accepted 7 May 2008

Available online 11 May 2008

#### Keywords:

Microwave

$\beta$ -Amino acid

Oxidative cleavage

1,4-Diazepin-5-one

### ABSTRACT

An efficient, high-yielding method has been developed for the synthesis of cycloalkane-fused and phenyl-substituted 1,4-diazepin-5-ones from  $\beta$ -amino acids. The process involves the oxidative cleavage of a terminal olefin bond and an acid-catalyzed, microwave-assisted intramolecular condensation step.

© 2008 Published by Elsevier Ltd.

Although the preparation and pharmaceutical properties of 1,4-benzodiazepines have been well documented, less attention has been paid to their saturated analogues. To the best of our knowledge, there has been only one report on the synthesis of cycloalkane-condensed 1,4-diazepinones.<sup>1</sup> However, certain 1,4-diazepin-5-ones exhibit significant biological properties, for example, as lymphocyte function-associated antigen-1 inhibitors,<sup>2</sup> anticonvulsants,<sup>3</sup> HIV-1 reverse transcriptase inhibitors,<sup>4</sup> pharmacophores for structure–activity relationships,<sup>5</sup> and most recently,  $\gamma$ -turn-like mimics.<sup>6</sup>

We report here an efficient, microwave (MW)-assisted method for the preparation of *cis*- and *trans*-cyclohexane- and *cis*-cyclopentane-condensed 5H-1,4,6,7-tetrahydro-1,4-diazepin-5-ones.

Starting from racemic *cis*- and *trans*-2-aminocyclohexane-carboxylic acids **1** and **12** and cispentacin<sup>7</sup> **2**, Cbz (benzyloxycarbonyl) protection of the amino group followed by amidation with allyl-methylamine or allyl(*p*-methoxy)benzylamine and subsequent oxidative cleavage of the carbon–carbon double bond furnished the corresponding formylmethyl carboxamides **6–8** and **14** (Scheme 1). An initial attempt, to perform the oxidative cleavage in a one-pot fashion, according to a literature procedure,<sup>8</sup> resulted in a low yield of the desired carbonyl compound **6**. However, the stepwise procedure reported for carbohydrate derivatives by Sharma and Nielsen<sup>9</sup> resulted in compounds **6–8** and **14** in overall yields of 71–79%.<sup>10</sup>

The reaction of *cis*-cyclohexane derivative **6** ( $R^1 = \text{Me}$ ) in the presence of 10 mol % *p*-TsOH in dry  $\text{CH}_2\text{Cl}_2$  in a MW reactor at 100 °C for only 5 min resulted in complete conversion to 1,4-diazepin-5-one **9** in 90% yield.<sup>11</sup> For cyclopentane derivative **7** ( $R^1 = \text{Me}$ ), application of the same method gave compound **10** in 81% yield. The method also proved adaptable for *trans*-cyclohexane derivative **14**, providing 1,4-diazepin-5-one **15** in an excellent (88%) yield. Broadening the scope of the transformation led to the synthesis of the PMB-protected derivative **8** ( $n = 2$ ,  $R^1 = \text{PMB}$ ), which furnished diazepinone **11** in 83% yield.


We next investigated the scope and limitations of the ring closure. 7-Phenyl-5H-1,4,6,7-tetrahydro-1,4-diazepin-5-one **18** was formed in 83% yield from compound **17**, itself synthesized from ( $\pm$ )- $\beta$ -phenylalanine<sup>12</sup> **16** (Scheme 2) via the process established for **1**, **2** and **12** in Scheme 1.

Our efforts to apply this method to anthranilic acid derivatives failed to yield the desired 1,4-benzodiazepin-5-ones. One possible explanation is that decreasing the nucleophilicity of the aniline nitrogen with a Cbz group inhibits nucleophilic attack on the aldehyde moiety. However, for *N*-methyl- and *N*-benzylanthranilamides, a similar method involving the application of acetal derivatives has been reported for the construction of 1,4-benzodiazepin-5-ones.<sup>13</sup>


In conclusion,  $\beta$ -amino acid-derived allylamides have been transformed efficiently into the corresponding aldehydes by applying a dihydroxylation/reduction/oxidative cleavage sequence. The formylmethyl derivatives obtained were cyclized to 1,4,6,7-tetrahydro-1,4-diazepin-5-ones in high yields in an acid-promoted

\* Corresponding author. Tel.: +36 62 545 564; fax: +36 62 545 705.

E-mail address: [fulop@pharm.u-szeged.hu](mailto:fulop@pharm.u-szeged.hu) (F. Fülöp).



**Scheme 1.** Reagents and conditions: (i) CbzCl, NaOH, CH<sub>2</sub>Cl<sub>2</sub>, rt (81–90%); (ii) (COCl)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 h, then Et<sub>3</sub>N, R<sup>1</sup>-allylamine, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight (83–88%); (iii) RuCl<sub>3</sub>·nH<sub>2</sub>O, NaIO<sub>4</sub>, CH<sub>3</sub>CN/EtOAc/H<sub>2</sub>O, 0 °C, 5 min, (b) NaBH<sub>4</sub>, THF/H<sub>2</sub>O, rt, 20 min, (c) NaIO<sub>4</sub>, THF/H<sub>2</sub>O, 0–5 °C, 30 min (71–79% for the three steps); (iv) *p*-TosOH, CH<sub>2</sub>Cl<sub>2</sub>, MW, 100 °C, 5 min (81–90%).



**Scheme 2.** Reagents and conditions: as in Scheme 1. Yields: (i) 83%, (ii) 79%, (iii) 63%, (iv) 83%.

MW-assisted condensation reaction. The method proved not to be restricted to cycloalkane-derived  $\beta$ -amino acids, and the nitrogens can be orthogonally protected (R<sup>1</sup> = PMB), which opens up the possibility for further transformations.

## Acknowledgement

We are grateful to the Hungarian Research Foundation (OTKA No. T049407) for financial support.

## References and notes

- Sathe, M.; Ghorpode, R.; Kaushik, M. P. *Chem. Lett.* **2006**, *35*, 86–87.
- Wattanasin, S.; Kallen, J.; Myers, S.; Guo, Q.; Sabio, M.; Ehrhardt, C.; Albert, R.; Hommel, U.; Weckbecker, G.; Welzenbach, K.; Weitz-Schmidt, G. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1217–1220.
- Murthy, K. S. K.; Knaus, E. E. *Drug Dev. Res.* **1999**, *46*, 155–162.
- Parker, K. A.; Dermatakis, A. J. *Org. Chem.* **1997**, *62*, 4164–4167.
- Sherrill, R. G. *Tetrahedron Lett.* **2007**, *48*, 7053–7056.
- Fenster, E.; Rayabarapu, D. K.; Zhang, M.; Mukherjee, S.; Hill, D.; Neuenswander, B.; Schoenen, F.; Hanson, P. R. *J. Comb. Chem.* **2008**, *10*, 230–234.
- Fülöp, F.; Martinek, T. A.; Tóth, G. K. *Chem. Soc. Rev.* **2006**, *35*, 323–334.
- Yang, D.; Zhang, C. *J. Org. Chem.* **2001**, *66*, 4814–4818.
- Sharma, P. K.; Nielsen, P. *J. Org. Chem.* **2004**, *69*, 5742–5745.
- Representative analytical data for aldehyde 8:** Colourless oil; yield 79%, <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>,  $\delta$ ): 9.41 (s, 1H), 7.30–7.39 (m, 5H), 7.02–7.10 (m, 2H), 6.81–6.90 (m, 2H), 5.46 (d, *J* 7.6 Hz, 1H), 5.11 (s, 2H), 4.51 (q, *J* 15.7 Hz, 2H), 3.91 (d, *J* 4.9 Hz, 2H), 3.76–3.85 (m, 4H), 3.29 (d, *J* 4.1 Hz, 1H), 2.17–2.28 (m, 1H), 1.92–2.02 (m, 1H), 1.37–1.77 (m, 6H). <sup>13</sup>C NMR (100.61 MHz, CDCl<sub>3</sub>,  $\delta$ ): 197.2, 174.5, 159.5, 155.9, 136.6, 129.5, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.5, 114.5, 114.3, 66.5, 55.8, 55.4, 55.2, 49.5, 40.5, 29.3, 26.4, 22.7, 22.2. Anal. Calcd for C<sub>25</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>: C, 68.47; H, 6.90; N, 6.39; O, 18.24. Found: C, 68.29; H, 6.73; N, 6.50; O, 18.39.
- General procedure for the preparation of 5H-1,4,6,7-tetrahydro-1,4-diazepin-5-ones 9–11, 15 and 18:** A CEM Discover 10 ml MW vial was charged with 0.3 mmol of compounds **6–8**, **14** or **17**, 5.7 mg (10 mol %) of *p*-toluenesulfonic acid and 2 ml of anhydrous dichloromethane, and was sealed with a Teflon cap. The vial was irradiated at 100 °C (200 W) for 5 min, with a 1.5 min ramp time. Next, the solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography on Merck silica gel (0.063–0.200 mm); elution with 1:1 *n*-hexane/ethyl acetate gave the pure compounds. **Compound 9:** white solid; yield 90%, mp 76–77 °C, <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>,  $\delta$ ): 7.31–7.47 (m, 5H), 6.40 (br s, 1H), 5.05–5.28 (m, 3H), 4.37 (d, *J* 10.0 Hz, 1H), 3.08 (s, 3H), 2.94 (s, 1H), 2.34 (d, *J* 12.5, 1H), 1.85–2.06 (m, 2H), 1.68–1.83 (m, 2H), 1.27–1.60 (m, 3H). <sup>13</sup>C NMR (100.61 MHz, CDCl<sub>3</sub>,  $\delta$ ): 171.9, 153.8, 136.2, 129.8, 129.2, 129.0, 128.8, 127.9, 114.3, 111.9, 68.6, 62.5, 43.9, 37.0, 36.6, 29.7, 25.8, 21.3. Anal. Calcd for C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>: C, 68.77; H, 7.05; N, 8.91; O, 15.27. Found: C, 69.04; H, 6.92; N, 8.75; O, 15.44. **Compound 10:** colourless oil; yield 81%, <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>,  $\delta$ ): 7.31–7.39 (m, 5H), 6.31 (d, *J* 6.5 Hz, 1H), 5.41 (d, *J* 6.5 Hz, 1H), 5.13–5.25 (m, 2H), 4.65–4.72 (m, 1H), 2.99–3.10 (m, 4H), 2.19–2.29 (m, 2H), 1.57–1.95 (m, 4H). <sup>13</sup>C NMR (100.61 MHz, CDCl<sub>3</sub>,  $\delta$ ): 173.3, 151.2, 136.6, 129.2, 129.1, 129.0, 128.8, 128.7, 119.8, 119.4, 69.4, 68.7, 48.6, 35.9, 29.8, 26.7, 22.4. Anal. Calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>: C, 67.98; H, 6.71; N, 9.33; O, 15.98. Found: C, 68.07; H, 6.82; N, 9.45; O, 15.74. **Compound 11:** colourless oil; yield 83%, <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>,  $\delta$ ): 7.29–7.39 (m, 5H), 7.19 (d, *J* 8.1 Hz, 2H), 6.84 (d, *J* 9.1 Hz, 2H), 6.39 (br s, 1H), 5.07–5.24 (m, 3H), 4.74 (d, *J* 14.1 Hz, 1H), 4.56 (d, *J* 14.1 Hz, 1H), 4.37 (d, *J* 10.1 Hz, 1H), 3.78 (s, 3H), 2.96 (s, 1H), 2.38 (d, *J* 12.1 Hz, 1H), 1.89–2.05 (m, 2H), 1.77 (d, *J* 14.1 Hz, 1H), 1.29–1.56 (m, 4H). <sup>13</sup>C NMR (100.61 MHz, CDCl<sub>3</sub>,  $\delta$ ): 171.9, 159.7, 136.5, 130.1, 130.0, 129.9, 129.8, 129.7, 129.6, 129.3, 129.2, 129.1, 129.0, 128.7, 114.7, 110.5, 68.8, 62.8, 55.9, 51.5, 44.3, 31.1, 30.0, 26.1, 21.7. Anal. Calcd for C<sub>25</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>: C, 71.41; H, 6.71; N, 6.66; O, 15.22. Found: C, 71.27; H, 6.90; N, 6.81; O, 15.37. **Compound 15:** white solid; yield 88%, mp 79–80 °C, <sup>1</sup>H NMR (400.13 MHz, CDCl<sub>3</sub>,  $\delta$ ): 7.31–7.42 (5H, m), 6.39 (1H, br s), 5.15–5.25 (m, 2H), 5.10 (d, *J* 4.0 Hz, 1H), 4.36 (d, *J* 10.1 Hz, 1H), 3.08 (s, 3H), 2.94 (br s, 1H), 2.34 (d, *J* 12.9 Hz, 1H), 1.86–2.02 (m, 2H), 1.71–1.83 (m, 1H), 1.22–1.61 (m, 4H). <sup>13</sup>C NMR (100.61 MHz, CDCl<sub>3</sub>,  $\delta$ ): 171.4, 153.3, 135.9, 128.7, 128.6, 128.5, 128.3, 128.1, 113.8, 111.4, 68.2, 62.1, 43.5, 36.2, 30.3, 29.2, 25.4, 21.0. Anal. Calcd for C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>: C, 68.77; H, 7.05; N, 8.91; O, 15.27. Found: C, 68.93; H, 7.11; N, 9.02; O, 15.13. **Compound 18:** colourless oil; yield 83%, <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400.13 MHz, 319.3 K) 7.12–7.34 (m, 10H), 6.64 (d, *J* 8.5 Hz, 1H), 5.74–5.78 (m,

- 1H), 5.39–5.46 (m, 1H), 5.12 (brs, 2H), 2.98–3.10 (m, 2H), 2.77 (s, 3H). <sup>13</sup>C NMR (100.61 MHz, CDCl<sub>3</sub>, δ): 169.9, 152.6, 136.4, 129.5, 129.4, 129.3, 129.2, 129.1, 128.2, 128.1, 125.9, 125.8, 125.7, 115.8, 113.8, 68.9, 60.8, 59.8, 43.1, 35.6. Anal. Calcd for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>: C, 71.41; H, 5.99; N, 8.33; O, 14.27. Found: C, 71.23; H, 6.12; N, 8.26; O, 14.20.
12. Torre, O.; Gotor-Fernandez, V.; Gotor, V. *Tetrahedron: Asymmetry* **2006**, *17*, 860–866.
13. (a) Wang, T.; Cloudsdale, I. S. *Synthesis* **2000**, 265–268; (b) Newkome, G. R. In *Comprehensive Heterocyclic Chemistry III*; Katritzky, A. R., Ramsden, C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier, 2008; Vol. 13, p 204.